Genetic Technologies (Genetic Technologies) Long-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Long-Term Debt?

Genetic Technologies's Long-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Genetic Technologies Long-Term Debt Historical Data

The historical data trend for Genetic Technologies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Long-Term Debt Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Debt

Get a 7-Day Free Trial

0.04

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Genetic Technologies (NAS:GENE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Genetic Technologies Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.